Clearmind Medicine (CMND) said Friday its alcohol use disorder oral drug candidate CMND-100 has reached the U.S., moving the drug closer to a planned phase 1/2a trial.
The trial will evaluate the drug's safety and efficacy in lowering alcohol consumption.
The study will be carried out at the Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine.
The Israeli trial will be conducted at IMCA (Israel Medical Center for Addiction) in Israel.
Price: 1.18, Change: +0.01, Percent Change: +0.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.